Johnson & Johnson made a tough call recently. They stopped a mid-stage trial for a new eczema drug. The drug, JNJ-5939, was supposed to help people with moderate to severe eczema. But it didn't work as well as hoped. The trial showed that the drug was safe to use. People didn't have bad reactions t
Johnson Matthey, a big name in the chemical industry, has some big changes happening at the top. Richard Pike, who was the finance chief, is now the new Chief Operating Officer. This means he will be in charge of making sure the company runs smoothly every day. At the same time, Alastair Judge, who
Stadium deals, often hailed as modern-day marvels of architecture and engineering, are also complex financial puzzles. Enter Stacy Sonnenberg, a financial whiz at Goldman Sachs, who's shaking things up with her innovative securitization strategies. Think of it like this: she's turning stadiums in
